Decibel Therapeutics (DBTX) – StreetInsider.com Reports
-
Baird Downgrades Decibel Therapeutics Inc (DBTX) to Neutral
-
Jones Trading Downgrades Decibel Therapeutics Inc (DBTX) to Hold
-
H.C. Wainwright Downgrades Decibel Therapeutics Inc (DBTX) to Neutral
-
Decibel Therapeutics (DBTX) to Resume Trading at 8 a.m.
-
Regeneron (REGN) to Acquire Decibel Therapeutics (DBTX) for Over $4 Per Share
-
Decibel Therapeutics (DBTX) Halted, News Pending
-
Decibel Therapeutics (DBTX) Announces Spanish Approval of Clinical Trial Application to Initiate Clinical Development of DB-OTO
-
Decibel Therapeutics (DBTX) Receives European Orphan Drug Designation for Lead Gene Therapy Candidate DB-OTO
-
Decibel Therapeutics (DBTX) Appoints Matthew Kapusta to its Board
-
SVB Leerink Downgrades Decibel Therapeutics Inc (DBTX) to Market Perform
-
Decibel Therapeutics (DBTX) Announces Approval of Clinical Trial Application in UK for DB-OTO
-
Decibel Therapeutics Inc (DBTX) PT Lowered to $10 at Citi
-
Decibel Therapeutics (DBTX) Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss
-
Decibel Therapeutics (DBTX) Appoints Kevin F. McLaughlin to its Board
-
Decibel Therapeutics (DBTX) Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTO
-
Decibel Therapeutics (DBTX) CFO to Resign
-
Decibel Therapeutics Inc (DBTX) PT Lowered to $12 at Citi
-
Decibel Therapeutics (DBTX) Reports Positive Interim Data of DB-020
-
Decibel Therapeutics Inc (DBTX) PT Lowered to $15 at Citi
-
Decibel Therapeutics Inc (DBTX) PT Lowered to $7 at Barclays
-
Decibel Therapeutics (DBTX) Files $200M Mixed Shelf Registration Statement
-
Decibel Therapeutics (DBTX) Reports Q4 Earnings, Provides Corporate Update
-
Decibel Therapeutics (DBTX) Issues Update on Progress of Lead Gene Therapy Product Candidate DB-OT, Presents Promising Preclinical Data Supporting Importance of Cell-Selective Transgene Expression
-
Decibel Therapeutics (DBTX) Announces Appointments of Alison Finger, MBA and Saraswathy Nochur, Ph.D. to its Board of Directors; Christine Poon Steps Down from Board
-
Jones Trading Starts Decibel Therapeutics Inc (DBTX) at Buy
-
Decibel Therapeutics (DBTX) Extends Research Term under Strategic Collaboration with Regeneron; Will Receives $10M Extension Fee
-
H.C. Wainwright Starts Decibel Therapeutics Inc (DBTX) at Buy
-
Decibel Therapeutics Inc (DBTX) PT Lowered to $20 at Citi
-
UPDATE: Baird Starts Decibel Therapeutics Inc (DBTX) at Outperform
-
Decibel Therapeutics (DBTX) Receives Orphan Drug and Rare Pediatric Disease Designations for DB-OTO for the Treatment of Otoferlin-Related Congenital Hearing Loss
-
Decibel Therapeutics Inc (DBTX) PT Lowered to $15 at SVB Leerink, Following Earnings
-
Decibel Therapeutics (DBTX) Appoints Dr. William H. Carson as Chairman of the Board of Directors
-
Decibel Therapeutics (DBTX) Added to Russell 2000 Index
-
SVB Leerink Starts Decibel Therapeutics Inc (DBTX) at Outperform
-
UPDATE: Barclays Starts Decibel Therapeutics Inc (DBTX) at Overweight
-
UPDATE: BMO Capital Starts Decibel Therapeutics Inc (DBTX) at Outperform
-
Citi Starts Decibel Therapeutics Inc (DBTX) at Buy
-
Russell to Add 39 IPOs to its Indexes on March 19, 16 Stocks Could See Significant Buy Pressure - Jefferies
-
Decibel Therapeutics (DBTX) IPO Opens 18% Higher
-
Decibel Therapeutics (DBTX) Prices 7.062M Share IPO at $18/Sh
Back to DBTX Stock Lookup